PsiOxus Therapeutics Ltd. products

Four transgenes: Producing an anti-FAP bispecific plus cytokines/chemokines. Currently in clinical trials in the US and UK. See our clinical trials page for more information. The aim of this study is to characterise the safety, tolerability and preliminary efficacy of NG-641 in patients with metastatic or advanced epithelial tumors.

Three transgenes: Producing membrane bound CD80 and secreted MIP1α and IFNa. As part of our expanding T-SIGn platform pipeline, this candidate is progressing through its IND enabling activities in readiness for entering clinical trials.

Two transgenes: Producing a secreted CD40 agonist monoclonal antibody. Currently in clinical trials in the US and UK. 

Three transgenes: Producing IL-12, IL-15 and a chemokine. As part of our expanding T-SIGn platform pipeline, this candidate is progressing through its IND enabling activities in readiness for entering clinical trials.

Novel transgene combinations. Our research team are developing a suite of viral vectors with new and innovative transgene inserts.